> top > docs > PMC:7556165 > spans > 71328-71683 > annotations

PMC:7556165 / 71328-71683 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T196 129-136 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T398 67-75 Species denotes COVID-19 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T422 0-355 Sentence denotes Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017).

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
1965 76-84 Species denotes patients Tax:9606
1966 316-324 Species denotes patients Tax:9606
1971 210-216 Chemical denotes rhACE2
1973 67-75 Disease denotes COVID-19 MESH:C000657245
1974 330-334 Disease denotes ARDS MESH:D012128

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T459 129-136 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T420 67-75 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T421 330-334 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1965 76-84 Species denotes patients Tax:9606
1966 316-324 Species denotes patients Tax:9606
1971 210-216 Chemical denotes rhACE2
1973 67-75 Disease denotes COVID-19 MESH:C000657245
1974 330-334 Disease denotes ARDS MESH:D012128

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T422 0-355 Sentence denotes Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017).